Navigation Links
SuperGen to Present Data at EORTC-NCI-AACR
Date:10/15/2008

DUBLIN, Calif., Oct. 15 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the company's plans to present five posters at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" on October 23 and 24, 2008.

SuperGen's presentations will review clinical and non-clinical advances in the following compounds: MP-470, SGI-1776 and SGI-1252. All presentations will occur as poster presentations.

Abstract Number/Title Date

Abstract 403: Clinical responses in highly refractory

solid tumor patients with oral MP-470, a multi-targeted

tyrosine kinase inhibitor, in combination with standard

of care chemotherapy regimens: preliminary report from

a multi-institutional phase-1b clinical trial Oct 23

Abstract 332: In vivo activity of SGI-1776, an orally

active Pim kinase inhibitor Oct 23

Abstract 426: Effects of food on the single-dose

pharmacokinetics of oral MP-470 capsules Oct 23

Abstract 480: MP-470, a novel multi-targeted tyrosine

kinase inhibitor targeting RAD 51 is not toxic to human

primary marrow stem cells at clinically relevant

concentrations Oct 24

Abstract 571: Modulation of JAK2 signaling pathways in

vitro and in vivo by SGI-1252, a potent small molecule

JAK2 inhibitor Oct 24

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

SuperGen, Inc. Dorland Global Public Relations

Timothy L. Enns Michael Beckerich (Media)

SVP, Corporate Communications Tel: (212) 677-7632

& Business Development mbeckerich@dorland.com

Tel: (925) 560-0100

Email: tenns@supergen.com

Mary M. Vegh

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
2. SuperGen Reports 2008 Second Quarter Financial Results
3. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
4. SuperGen Reports 2008 First Quarter Financial Results
5. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
6. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
7. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
8. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
9. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
10. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
11. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalindâ„¢, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
Breaking Biology Technology:
(Date:8/23/2017)... public,s help is being enlisted in what,s thought to be the biggest ... human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to date ... project's goal is to help advance scientific knowledge of the role of ... The ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):